Planned sale of 5,967 Neumora (NASDAQ: NMRA) shares disclosed

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. reported a planned Rule 144 sale of common stock by an affiliated holder. The notice covers 5,967 shares of common stock, with an aggregate market value of $21,093.35, to be sold through Merrill Lynch on NASDAQ around 02/17/2026.

The shares were acquired on 02/14/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan. Neumora reports that 167,089,114 shares of common stock were outstanding, providing context for the size of this prospective sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	5967	21093.35	167089114	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/14/2026	Vesting of restricted stock unit award	Neumora Therapeutics, Inc.			5967	02/14/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Neumora Therapeutics (NMRA) disclose in this Form 144 filing?

Neumora Therapeutics discloses a planned sale of 5,967 common shares under Rule 144. The filing outlines the share amount, market value, acquisition method, broker, and intended trading venue, giving investors visibility into this prospective insider-related stock sale.

How many Neumora (NMRA) shares are planned to be sold and at what value?

The notice covers an intended sale of 5,967 Neumora common shares with an aggregate market value of $21,093.35. This provides a concrete size for the proposed Rule 144 transaction relative to Neumora’s overall equity base.

How were the Neumora (NMRA) shares in the Form 144 acquired?

The 5,967 Neumora common shares were acquired on 02/14/2026 through vesting of a restricted stock unit award. The award was granted as part of Neumora’s equity compensation plan, rather than being purchased for cash in the open market.

When is the planned sale date for the Neumora (NMRA) shares under Rule 144?

The Form 144 states an approximate sale date of 02/17/2026 for the 5,967 Neumora shares. This timing indicates the holder’s intention to begin selling shortly after the restricted stock units vested and became common shares.

Which broker and exchange are involved in the Neumora (NMRA) Form 144 sale?

The planned sale will use Merrill Lynch as broker, with trades on NASDAQ. The filing lists Merrill Lynch’s New York address and specifies NASDAQ as the securities exchange where the 5,967 Neumora common shares are expected to be sold.

How does the planned Neumora (NMRA) share sale compare with shares outstanding?

The filing notes 167,089,114 Neumora common shares outstanding, against which 5,967 shares are planned for sale. This comparison shows the prospective Rule 144 transaction is small relative to the total share count disclosed.